← Back to Search

Antioxidant

Study of Sulphoraphane in Chronic Kidney Disease

Phase 1
Waitlist Available
Led By Thu H Le, MD, FAHA
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up prior to initial dose on day 7 and 1, 2, 4, and 8 hours post-dose
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing sulforaphane, a compound that helps protect cells from damage, in patients with chronic kidney disease. The goal is to find a safe dose for these patients. Sulforaphane works by boosting the body's natural defenses against harmful molecules. It has been studied for its protective effects against various types of kidney damage, including those caused by certain medications and toxins.

Eligible Conditions
  • Chronic Kidney Disease
  • Renal Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~prior to initial dose on day 7 and 1, 2, 4, and 8 hours post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and prior to initial dose on day 7 and 1, 2, 4, and 8 hours post-dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Area Under the Concentration-Time Curve (AUC 0-8h) in Plasma
Area Under the Concentration-Time Curve (AUC 0-8h) in Urine
Number of Participants With an Adverse Event

Side effects data

From 2023 Phase 2 trial • 43 Patients • NCT03232138
81%
Others
62%
Flatulence
48%
Diarrhea
43%
Insomnia
38%
Stomachache
33%
Mood Alteration
33%
Constipation
29%
Dry Mouth
29%
Nausea
29%
Dizziness
24%
Tremor
19%
Belching
14%
Distension
14%
Headache
10%
Vomiting
5%
Bad taste
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sulforaphane (Study Drug)
Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: 4 tablets of SulforaphaneExperimental Treatment1 Intervention
Participants will be given 4 extra strength tablets per day
Group II: 2 tablets of SulforaphaneExperimental Treatment1 Intervention
Participants will be given 2 extra strength tablets per day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sulforaphane
2016
Completed Phase 3
~530

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,464 Previous Clinical Trials
4,337,435 Total Patients Enrolled
University of RochesterLead Sponsor
872 Previous Clinical Trials
550,073 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,840 Previous Clinical Trials
8,172,105 Total Patients Enrolled
Thu H Le, MD, FAHAPrincipal InvestigatorDivision of Nephrology Chief
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top